Michelle Yong
@michyong.bsky.social
ID Physician Associate Prof immune compromised hosts #TxID #CMV #Fungal #viral infections. Royal Melbourne Hospital, Peter MacCallum Cancer Centre. University of Melbourne. Exec Council ICHS
Reposted by Michelle Yong
Interesting!
🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…
Full link here: academic.oup.com/cid/advance-ar…
Full link here: academic.oup.com/cid/advance-ar…
September 1, 2025 at 12:32 PM
Interesting!
Reposted by Michelle Yong
Study: Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.
Published: 28 August 2025
Source: academic.oup.com/cid/advance-...
Published: 28 August 2025
Source: academic.oup.com/cid/advance-...
August 30, 2025 at 1:33 AM
Study: Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.
Published: 28 August 2025
Source: academic.oup.com/cid/advance-...
Published: 28 August 2025
Source: academic.oup.com/cid/advance-...
Reposted by Michelle Yong
Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients.
"The research... showed that a nasal spray containing interferon-alpha (IFN-α), a naturally occurring protein with broad antiviral activity, could reduce the risk of COVID-19 infection by 40% compared to placebo."
"The research... showed that a nasal spray containing interferon-alpha (IFN-α), a naturally occurring protein with broad antiviral activity, could reduce the risk of COVID-19 infection by 40% compared to placebo."
Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients - Peter MacCallum Cancer Centre
www.petermac.org
August 30, 2025 at 1:33 AM
Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients.
"The research... showed that a nasal spray containing interferon-alpha (IFN-α), a naturally occurring protein with broad antiviral activity, could reduce the risk of COVID-19 infection by 40% compared to placebo."
"The research... showed that a nasal spray containing interferon-alpha (IFN-α), a naturally occurring protein with broad antiviral activity, could reduce the risk of COVID-19 infection by 40% compared to placebo."
Reposted by Michelle Yong
With COVIDhge, we previously ✍🏼 about IFN therapy for COVID, based on findings that 🧬mutations or auto-Abs to type I IFN caused severe COVID.
Now, an RCT shows this concept extends more broadly👇🏼
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients academic.oup.com/cid/article/...
Now, an RCT shows this concept extends more broadly👇🏼
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients academic.oup.com/cid/article/...
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
In this randomized, double-blind, placebo-controlled trial, 433 participants received daily nasal spray 40 000 IU IFN-α or placebo for 3 months. The primar
academic.oup.com
August 31, 2025 at 7:52 PM
With COVIDhge, we previously ✍🏼 about IFN therapy for COVID, based on findings that 🧬mutations or auto-Abs to type I IFN caused severe COVID.
Now, an RCT shows this concept extends more broadly👇🏼
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients academic.oup.com/cid/article/...
Now, an RCT shows this concept extends more broadly👇🏼
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients academic.oup.com/cid/article/...
Reposted by Michelle Yong
In this RCT, 433 adults w/cancer randomized to daily IFN-alpha or placebo nasal spray. Incidence of COVID was significantly different at 8.3% w/ IFN-alpha vs 14.4% in control, w/ no difference in other resp viruses (similar in vaccinated subgroup)… #IDSky
academic.oup.com/cid/advance-...
academic.oup.com/cid/advance-...
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
In this randomized, double-blind, placebo-controlled trial, 433 participants received daily nasal spray 40 000 IU IFN-α or placebo for 3 months. The primar
academic.oup.com
September 4, 2025 at 12:32 PM
In this RCT, 433 adults w/cancer randomized to daily IFN-alpha or placebo nasal spray. Incidence of COVID was significantly different at 8.3% w/ IFN-alpha vs 14.4% in control, w/ no difference in other resp viruses (similar in vaccinated subgroup)… #IDSky
academic.oup.com/cid/advance-...
academic.oup.com/cid/advance-...
🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…
Full link here: academic.oup.com/cid/advance-ar…
Full link here: academic.oup.com/cid/advance-ar…
September 1, 2025 at 12:21 PM
🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…
Full link here: academic.oup.com/cid/advance-ar…
Full link here: academic.oup.com/cid/advance-ar…
Reposted by Michelle Yong
Day 2 of the @petermaccc.bsky.social Research Symposium opened with A/Prof @michyong.bsky.social plenary on "Transforming the care of Infectious Diseases in Cancer Patients." Discussing groundbreaking research and future directions in fungal, viral, bacterial, and vaccine clinical trials.
May 9, 2025 at 2:54 AM
Day 2 of the @petermaccc.bsky.social Research Symposium opened with A/Prof @michyong.bsky.social plenary on "Transforming the care of Infectious Diseases in Cancer Patients." Discussing groundbreaking research and future directions in fungal, viral, bacterial, and vaccine clinical trials.
Reposted by Michelle Yong
Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!
May 15, 2025 at 12:34 AM
Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!
Reposted by Michelle Yong
Prof Monica Slavin at the meet the experts on Mycology clinical trials- have you participated?#escmidglobal
April 12, 2025 at 9:06 AM
Prof Monica Slavin at the meet the experts on Mycology clinical trials- have you participated?#escmidglobal
Reposted by Michelle Yong
We are excited for #ESCMIDGLOBAL - the premier event for Infectious Diseases and Microbiology hosted by @escmid.bsky.social in Vienna, Austria! 🌍
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.
April 8, 2025 at 3:26 AM
We are excited for #ESCMIDGLOBAL - the premier event for Infectious Diseases and Microbiology hosted by @escmid.bsky.social in Vienna, Austria! 🌍
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.
Reposted by Michelle Yong
Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽
April 4, 2025 at 4:00 AM
Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽
Reposted by Michelle Yong
Join A/Professor @michyong.bsky.social this Thursday 3rd of April at 10 am ET, for the @ichs-global.bsky.social Early Career virtual networking session to connect, collaborate, and shape the future of Early Career programs!
To learn more and sign up: ichs.wildapricot.org/page-1863364
To learn more and sign up: ichs.wildapricot.org/page-1863364
International Immunocompromised Host Society - Early Career Session
ichs.wildapricot.org
April 1, 2025 at 12:06 AM
Join A/Professor @michyong.bsky.social this Thursday 3rd of April at 10 am ET, for the @ichs-global.bsky.social Early Career virtual networking session to connect, collaborate, and shape the future of Early Career programs!
To learn more and sign up: ichs.wildapricot.org/page-1863364
To learn more and sign up: ichs.wildapricot.org/page-1863364
Reposted by Michelle Yong
Great 1st day at Australasian Society for Infectious Diseases meeting!
@michyong.bsky.social led an insightful CMV symposium
@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG
@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space
@michyong.bsky.social led an insightful CMV symposium
@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG
@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space
April 3, 2025 at 11:01 PM
Great 1st day at Australasian Society for Infectious Diseases meeting!
@michyong.bsky.social led an insightful CMV symposium
@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG
@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space
@michyong.bsky.social led an insightful CMV symposium
@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG
@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space
Reposted by Michelle Yong
Hello, Bluesky!👋 We are excited to connect with you!🌟
Europe PMC is an open database of global life science research - discover articles, preprints, theses, grants, and more. We talk about scholarly communication, open science, bioinformatics, and meta research. Follow us and join the conversation!
Europe PMC is an open database of global life science research - discover articles, preprints, theses, grants, and more. We talk about scholarly communication, open science, bioinformatics, and meta research. Follow us and join the conversation!
January 28, 2025 at 9:45 AM
Hello, Bluesky!👋 We are excited to connect with you!🌟
Europe PMC is an open database of global life science research - discover articles, preprints, theses, grants, and more. We talk about scholarly communication, open science, bioinformatics, and meta research. Follow us and join the conversation!
Europe PMC is an open database of global life science research - discover articles, preprints, theses, grants, and more. We talk about scholarly communication, open science, bioinformatics, and meta research. Follow us and join the conversation!
Reposted by Michelle Yong
Kicking off the #pharmacysymposium
We have @michyong.bsky.social highlighting the use of marabivir in tricky #ID populations #CMV and real world use beyond the clinical trials. (With promising clinical effectiveness) #antiviralstewardship
#antimicrobials2025
We have @michyong.bsky.social highlighting the use of marabivir in tricky #ID populations #CMV and real world use beyond the clinical trials. (With promising clinical effectiveness) #antiviralstewardship
#antimicrobials2025
February 22, 2025 at 2:31 AM
Kicking off the #pharmacysymposium
We have @michyong.bsky.social highlighting the use of marabivir in tricky #ID populations #CMV and real world use beyond the clinical trials. (With promising clinical effectiveness) #antiviralstewardship
#antimicrobials2025
We have @michyong.bsky.social highlighting the use of marabivir in tricky #ID populations #CMV and real world use beyond the clinical trials. (With promising clinical effectiveness) #antiviralstewardship
#antimicrobials2025
Reposted by Michelle Yong
If it's written by @kottonnelson.bsky.social, it is a must read!
Concise expert insight into the utility of Immune monitoring assays for Cytomegalovirus.
journals.lww.com/transplantjo...
Concise expert insight into the utility of Immune monitoring assays for Cytomegalovirus.
journals.lww.com/transplantjo...
Immune Monitoring Assays: Predicting Cytomegalovirus and... : Transplantation
An abstract is unavailable.
journals.lww.com
February 21, 2025 at 8:57 PM
If it's written by @kottonnelson.bsky.social, it is a must read!
Concise expert insight into the utility of Immune monitoring assays for Cytomegalovirus.
journals.lww.com/transplantjo...
Concise expert insight into the utility of Immune monitoring assays for Cytomegalovirus.
journals.lww.com/transplantjo...
Thanks @sonkoning.bsky.social . We’ve learnt so much over the years… more promising therapies to come
What’s on the horizon for COVID for immunocompromised patients? Monoclonals, interferon nasal spray, T-cell therapy @michyong.bsky.social #antimicrobials2025 #ASA
February 21, 2025 at 6:49 AM
Thanks @sonkoning.bsky.social . We’ve learnt so much over the years… more promising therapies to come
What a great meeting! @ausantibiotics.bsky.social
#ASA2025 in Melbourne! 🌟
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!
February 21, 2025 at 6:46 AM
What a great meeting! @ausantibiotics.bsky.social
Reposted by Michelle Yong
#ASA2025 in Melbourne! 🌟
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!
February 21, 2025 at 5:11 AM
#ASA2025 in Melbourne! 🌟
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!
Reposted by Michelle Yong
Happy International Women in Science Day!
With over 85% of our cohort being women, we are dedicated to promoting, supporting, and strengthening women in science!
Discover the achievements of these women here:
cancerandinfections.org/phd-pathways
@michyong.bsky.social @abbydouglas.bsky.social
With over 85% of our cohort being women, we are dedicated to promoting, supporting, and strengthening women in science!
Discover the achievements of these women here:
cancerandinfections.org/phd-pathways
@michyong.bsky.social @abbydouglas.bsky.social
February 11, 2025 at 5:15 AM
Happy International Women in Science Day!
With over 85% of our cohort being women, we are dedicated to promoting, supporting, and strengthening women in science!
Discover the achievements of these women here:
cancerandinfections.org/phd-pathways
@michyong.bsky.social @abbydouglas.bsky.social
With over 85% of our cohort being women, we are dedicated to promoting, supporting, and strengthening women in science!
Discover the achievements of these women here:
cancerandinfections.org/phd-pathways
@michyong.bsky.social @abbydouglas.bsky.social
Reposted by Michelle Yong
Really interesting paper by my colleagues at @domucla.bsky.social - and fits with my own thoughts about the utility/pitfalls of plasma mcfDNA (including low yield of fungal pickup) as well as giving some ideas for future diagnostic stewardship if incorporated into practice @jschaenmanmd.bsky.social
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay | Infection Control & Hospital Epidemiology | Cambridge Core
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay
www.cambridge.org
February 2, 2025 at 2:22 AM
Really interesting paper by my colleagues at @domucla.bsky.social - and fits with my own thoughts about the utility/pitfalls of plasma mcfDNA (including low yield of fungal pickup) as well as giving some ideas for future diagnostic stewardship if incorporated into practice @jschaenmanmd.bsky.social
Congratulations Tori!
Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....
Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM
In this trial involving patients with hematologic cancers, the immune responses that
were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.
www.nejm.org
January 18, 2025 at 9:54 PM
Congratulations Tori!
Reposted by Michelle Yong
New virtual meeting for Immunocompromised Host Society: Addressing the Landscape of CMV Management in Transplant Recipients. Free to members or $25 plus a free membership for those not already members!
Forward on to your residents, fellows, grad students, and international colleagues
#TxID #CMV
Forward on to your residents, fellows, grad students, and international colleagues
#TxID #CMV
November 18, 2024 at 7:50 PM
Thanks @germhuntermd.bsky.social ! Wow the ICH #TxID group is growing by the day. Just updated and followed - thanks for making it easier to find our friends and colleagues.
Welcome @michaelisonmd.bsky.social to #TxID and #IDSky!
Here is a starter pack to help you find the ol' gang go.bsky.app/95rzmLi
And here is a link to a feed you can pin that will index all Skeets (yes that's what we call them) tagged with TxID bsky.app/profile/did:...
Here is a starter pack to help you find the ol' gang go.bsky.app/95rzmLi
And here is a link to a feed you can pin that will index all Skeets (yes that's what we call them) tagged with TxID bsky.app/profile/did:...
November 17, 2024 at 12:02 AM
Thanks @germhuntermd.bsky.social ! Wow the ICH #TxID group is growing by the day. Just updated and followed - thanks for making it easier to find our friends and colleagues.
Australian adoption paperwork is underway @kottonnelson.bsky.social !Love these photos!
Loving my time in Melbourne as the Forbes Fellow. Such a great city. Awesome parks and green space. Love the flat whites! Gorgeous birds of paradise, always reminds me of my mom - her favorite flowers. Feel very lucky to be part of such a great medical community for a week!!
November 16, 2024 at 1:23 AM
Australian adoption paperwork is underway @kottonnelson.bsky.social !Love these photos!